Navidea Biopharmaceuticals (NAVB +2.3%) is set to close higher after announcing that the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing intends to switch to using NAVB's Fluorine-18 labeled amyloid imaging candidate, NAV4694, for its research initiative on Alzheimer's disease and mild cognitive impairment.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs